コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
2 ening renal function during the treatment of decompensated heart failure.
3 e, was approved for the treatment of acutely decompensated heart failure.
4 idate drug in clinical trials to treat acute decompensated heart failure.
5 ated patients sometimes present acutely with decompensated heart failure.
6 rapy (CRT) in patients admitted for advanced decompensated heart failure.
7 iming of diuretics among patients with acute decompensated heart failure.
8 cting PCWP in patients admitted for advanced decompensated heart failure.
9 ents (80.5%) who were hospitalized for acute decompensated heart failure.
10 164 individuals (99% men) hospitalized with decompensated heart failure.
11 e events in hospitalized patients with acute decompensated heart failure.
12 that impair glucose transport induce acute, decompensated heart failure.
13 des (proBNP) in patients admitted with acute decompensated heart failure.
14 and quality of care for patients with acute decompensated heart failure.
15 act on renal function in patients with acute decompensated heart failure.
16 ransition from stable cardiac hypertrophy to decompensated heart failure.
17 ean 7.3 years for development of incident or decompensated heart failure.
18 serve as a marker for the severity of acute decompensated heart failure.
19 efficacy of UF versus standard care in acute decompensated heart failure.
20 er current investigation in the treatment of decompensated heart failure.
21 ategies for treatment of patients with acute decompensated heart failure.
22 rGLP-1 may be a useful metabolic adjuvant in decompensated heart failure.
23 shown to be efficacious in the treatment of decompensated heart failure.
24 s predict outcomes of patients admitted with decompensated heart failure.
25 ent in hemodynamic function in patients with decompensated heart failure.
26 n the short-term management of patients with decompensated heart failure.
27 calcium-sensitizing agent, in patients with decompensated heart failure.
28 he progression of compensated hypertrophy to decompensated heart failure.
29 chaemia-reperfusion, cardiac hypertrophy and decompensated heart failure.
30 reserved ejection fraction, as well as acute decompensated heart failure.
31 halting the progression from compensated to decompensated heart failure.
32 presenting with cardiogenic shock, and acute decompensated heart failure.
33 frequent cause for hospitalization in acute decompensated heart failure.
34 heart failure sometimes present acutely with decompensated heart failure.
35 ide on renal function in patients with acute decompensated heart failure.
36 nostic factors in patients hospitalized with decompensated heart failure.
37 affect renal function in patients with acute decompensated heart failure.
38 f 487 patients aged >/=75 years admitted for decompensated heart failure.
39 l and a key measure of treatment efficacy in decompensated heart failure.
40 ients hospitalized with a diagnosis of acute decompensated heart failure.
41 gestion, and outcomes in patients with acute decompensated heart failure.
42 tes acute respiratory distress syndrome from decompensated heart failure.
43 g sustained decongestion during treatment of decompensated heart failure.
44 xtracorporeal membrane oxygenation for acute decompensated heart failure.
45 dia (VT) in hospitalized patients with acute decompensated heart failure.
46 dent cohort of 75 subjects treated for acute decompensated heart failure.
47 apy for the treatment of patients with acute decompensated heart failure.
48 xtracorporeal membrane oxygenation for acute decompensated heart failure, 1-year survival was 42%, bu
49 ortality in patients hospitalized with acute decompensated heart failure: 4 HF-specific mortality pre
50 of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure), 7,141 patients hospitalize
52 tions associated with circulating LPS (e.g., decompensated heart failure, acute and chronic infection
53 nitroprusside (SNP) for patients with acute decompensated heart failure (ADHF) and low-output states
54 is and renal function in patients with acute decompensated heart failure (ADHF) and renal impairment
55 de (iBNP) and early intervention for acutely decompensated heart failure (ADHF) and whether these var
57 M) code criteria, do not differentiate acute decompensated heart failure (ADHF) from chronic stable H
58 Estimates of the numbers and rates of acute decompensated heart failure (ADHF) hospitalization are c
62 ure), 7,141 patients hospitalized with acute decompensated heart failure (ADHF) were randomized to re
63 in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving pa
64 d volume overload are the hallmarks of acute decompensated heart failure (ADHF), and loop diuretics h
69 ined tachyarrhythmia (atrial/ventricular) or decompensated heart failure admission/transplantation/de
72 ning renal function, is also common in acute decompensated heart failure, although the definition of
73 s, the hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) u
74 al function during hospitalization for acute decompensated heart failure and associated outcomes.
75 ide on renal function in patients with acute decompensated heart failure and baseline renal dysfuncti
77 HF) trials during hospitalization with acute decompensated heart failure and clinical congestion.
78 is a primary therapeutic objective in acute decompensated heart failure and commonly monitored with
79 tal of 40 consecutive patients with advanced decompensated heart failure and CRT implanted >3 months,
80 Ritonavir and lopinavir precipitated acute, decompensated heart failure and death from pulmonary ede
81 intravenous (IV) diuretics in patients with decompensated heart failure and diuretic resistance resu
82 tal practice patterns of NIPPV use for acute decompensated heart failure and their relationship with
83 d arginine metabolism in patients with acute decompensated heart failure and to explore possible mech
84 s admitted to a single institution for acute decompensated heart failure and treated with UF: HFLEF (
85 fylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Asses
86 fylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Asses
87 fylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Asses
88 fylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Asses
89 nificantly associated with increased risk of decompensated heart failure and/or development of clinic
90 infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardiovascul
91 neous nature of patients admitted with acute decompensated heart failure, and the limitations of the
92 of hypotension while hospitalized with acute decompensated heart failure are not well understood.
93 e transition from compensated hypertrophy to decompensated heart failure as a result of reduced phosp
94 e a context for Acute Study of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, we design
95 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), we assessed fac
96 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure [ASCEND-HF]; NCT00475852).
97 d all consecutive patients hospitalized with decompensated heart failure at Mayo Clinic Hospitals in
98 , and unplanned clinic visits to treat acute decompensated heart failure based on the blinded adjudic
100 patients (acute myocardial infarction, acute decompensated heart failure, biventricular failure, and
101 in the management of low output syndrome and decompensated heart failure but their effect on mortalit
102 component of therapy for patients with acute decompensated heart failure, but there are few prospecti
103 should be considered for patients with acute decompensated heart failure, but timing of implantation
104 E-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trials during h
105 ty of ultrafiltration in patients with acute decompensated heart failure complicated by persistent co
106 ic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal R
107 y improves cardiac function in patients with decompensated heart failure due to severe left ventricul
109 ospective consecutive patients with advanced decompensated heart failure (ejection fraction < or =30%
111 e, hemoconcentration during the treatment of decompensated heart failure has been associated with red
112 anagement strategy for patients with acutely decompensated heart failure has been limited to the use
113 progression from compensated hypertrophy to decompensated heart failure have not been thoroughly def
115 effect of tezosentan in patients with acute decompensated heart failure (HF) associated with acute c
116 -type natriuretic peptide) in the therapy of decompensated heart failure (HF) by assessing the hemody
118 ht to test the hypothesis that patients with decompensated heart failure (HF) lose a compensatory pro
119 ltrafiltration (SCUF) in patients with acute decompensated heart failure (HF) refractory to intensive
120 outcomes of patients hospitalized for acute decompensated heart failure (HF) with preserved systolic
121 designed to normalize loading conditions in decompensated heart failure (HF), reduces neurohormonal
125 tion of chronic oral medication during acute decompensated heart failure hospitalization may not be a
126 xtracorporeal membrane oxygenation for acute decompensated heart failure (i.e., cardiogenic shock com
127 xtracorporeal membrane oxygenation for acute decompensated heart failure in our ICU (67% of them had
128 prevents the transition from compensated to decompensated heart failure in part via upregulation of
129 technology for inpatient management of acute decompensated heart failure in patients with volume over
130 mass spectrometry in subjects with advanced decompensated heart failure in the intensive care unit (
132 association between air pollution and acute decompensated heart failure including hospitalisation an
133 outcome of hospitalization for management of decompensated heart failure, initiation of mechanical ci
135 Hypotension while hospitalized for acute decompensated heart failure is an independent risk facto
137 SBP reduction) during the treatment of acute decompensated heart failure is strongly and independentl
139 not improve renal function in patients with decompensated heart failure, mild chronic renal insuffic
142 rom >100,000 hospitalizations from the Acute Decompensated Heart Failure National Registry (ADHERE) d
143 h heart failure without CRT-D from the Acute Decompensated Heart Failure National Registry (ADHERE) h
144 of observational patient data from the Acute Decompensated Heart Failure National Registry (ADHERE),
145 January 2004 that were recorded in the Acute Decompensated Heart Failure National Registry (ADHERE).
148 re National Registry-United States and Acute Decompensated Heart Failure National Registry-Internatio
149 re National Registry-United States and Acute Decompensated Heart Failure National Registry-Internatio
150 amined 196 770 AHF admissions from the Acute Decompensated Heart Failure National Registry-United Sta
152 ped from 3 clinical databases (ADHERE [Acute Decompensated Heart Failure National Registry], EFFECT s
158 l arrhythmias in this population can lead to decompensated heart failure or thromboembolism and thera
159 ion rates, morbidity, and mortality of acute decompensated heart failure, other newer approaches, suc
160 arginine metabolism was observed in advanced decompensated heart failure, particularly with pulmonary
161 gen/creatinine ratio (BUN/Cr) could identify decompensated heart failure patients likely to experienc
162 was then prospectively validated in 50 acute decompensated heart failure patients using meticulously
163 is population with outcomes similar to acute decompensated heart failure patients with low left ventr
165 with greater iBNP levels (Registry for Acute Decompensated Heart Failure Patients; NCT00366639).
168 Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmis
170 itide is approved for the treatment of acute decompensated heart failure, retrospective analyses have
171 least 40 years and hospitalization for acute decompensated heart failure, severe systemic infection w
173 r arrhythmias in this population can lead to decompensated heart failure, syncope, and sudden cardiac
174 ement of our understanding and management of decompensated heart failure syndromes but for the transl
176 k period during which interventions to avert decompensated heart failure that necessitates hospitaliz
178 d trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide admini
179 rt study of 218 patients admitted with acute decompensated heart failure to the Nashville VA Medical
180 oral neurohormonal antagonists during acute decompensated heart failure treatment negatively influen
182 y of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized 7,141 hosp
183 ventilation (NIPPV) for patients with acute decompensated heart failure was introduced almost 20 yea
184 Pressure Measurements in Patients With Acute Decompensated Heart Failure) was a single-center prospec
185 ents hospitalized for the treatment of acute decompensated heart failure will experience significant
186 ients >/=55 years of age admitted with acute decompensated heart failure with preserved ejection frac
187 mong hospitals in the use of NIPPV for acute decompensated heart failure without evidence for differe
188 al involving patients hospitalized for acute decompensated heart failure, worsened renal function, an
189 assigned a total of 188 patients with acute decompensated heart failure, worsened renal function, an
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。